Recently, the Children Oncology Group explored the role of these genetic lesions in a large retrospective cohort of pediatric and young adult de novo AML patients (aged 0–29.8 years), showing that CREBBP-disrupted cases experience worse event-free survival and increased relapse risk compared to wild type ones [142]. This evidence concerns the gene CREBBP and acute myeloid leukemia.